-
BTK inhibitors vs BCL2 inhibitors in untreated CLL_Susan O'Brien, MD; #DDHO2021
2:30
-
Jennifer R. Brown, MD, PhD; Dana-Farber Cancer Institute #BtC_ASCO21
15:33
Dr. Jennifer Brown reviews Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory CLL.
-
Nicole Lamanna, MD; Columbia University #BtC_ASCO21
16:56
Dr. Nicole Lamanna discusses Practical Issues in Treating CLL: Sequencing, Oral Adherence, Managing Adverse Events, and MRD Analysis.
-
Matthew Davids, MD, MMSc; Dana-Farber Cancer Inst. #BtC_ASCO21
15:27
Dr. Matthew Davids reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for CLL.
-
William G. Wierda, M.D., Ph.D.; The University of Texas MD Anderson Cancer Center; 5Live; #ASCO2021
5:42
-
Susan O'Brien, MD; University of California Irvine; 5Live; #ASCO2021
9:34
-
Matthew S. Davids, MD, MMSc; Dana-Farber Cancer Institute; 5Live; #ASCO2021
4:23
-
Meghan Thompson, MD; Memorial Sloan Kettering Cancer Center; 5Live; #ASCO2021
4:54
-
Nicole Lamanna, MD; Columbia University Medical Center; 5Live; #ASCO2021
7:21
-
John G. Gribben, MD, DSc, FRCP, FRCPath, FMed Sci; Barts Cancer Institute, Queen Mary University of London; 5Live; #ASCO2021
4:24
-
Jennifer Woyach, MD; The Ohio State University Comprehensive Cancer Center; 5Live; #ASCO2021
4:19
- Next Page
